Iron Overload Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Iron Overload indicates a physical condition resulting in increased total body iron stores, with or without organ dysfunction. In other words, it refers to a cluster of genetic or acquired conditions that result in the extra accumulation of iron in the body. Since excess iron is toxic to the cells, its collection can lead to permanent tissue damage, resulting in organ failure if left untreated for a prolonged period. Iron Overload is caused by an inherited disorder called hereditary hemochromatosis (HH) or is acquired in patients with certain conditions that need frequent blood transfusions. Iron homeostasis depends on a complex feedback mechanism between body iron requirements and intestinal absorption. Humans lack a physiological mechanism for the excretion of excess iron. The hormone hepcidin, a 25-amino acid peptide, is produced mainly in the liver and secreted into the blood and is now recognized as the critical regulator of iron homeostasis. Any disruptions in the regulation of hepcidin are a cause of many disorders related to iron homeostasis. Iron overload syndromes are broadly divided into inherited or Primary iron overload called hereditary hemochromatosis (HH) and Secondary iron overload syndromes. The former is a genetic disorder that causes the body to absorb excessive iron from the diet. The most common subtype of the above is HFE related HH caused by mutations in the human hemochromatosis gene (HFE). The HFE protein regulates the absorption of iron by controlling hepcidin production.
·
The prevalence of primary and secondary iron
overload syndromes cases varies from 325 to 385 cases per 100,000 population in
the USA.
Thelansis’s
“Iron Overload Disorder Market Outlook, Epidemiology, Competitive Landscape,
and Market Forecast Report – 2023 To 2033" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Iron
Overload Disorder treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Iron Overload
Disorder across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Iron
Overload Disorder Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Iron
Overload Disorder, Iron Overload Disorder market
outlook, Iron Overload Disorder competitive
landscape, Iron Overload Disorder market
forecast, Thelansis, Primary market research, KOL insights, Competitive
Intelligence (CI)
Comments
Post a Comment